Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
who said there is a breach of contract ...who said they are not moving in...stop the crap and slander...they just signed the lease and that location has nothing to do with the merger and the location that business is in...
you told everyone on here you sold and lost a thousand dollars...immediately you started your vengeful rampage on this stock and everyone else...you should of never been in a penny stock to begin with and the fact that you only lost a thousand dollars tells me you don't have a portfolio that you claim to have...otherwise a measly thousand dollars would not mean that much...you can make that back in a day on another stock instead of spending the amount of time you do to trash this one...
Jurisdiction: NEVADA....
has nothing to do with where they are incorporated....
how many times does it take to get in your head they are inc. in Nevada...the site you keep providing our of the goodness of your heart to help everyone will not show a corporation from another state...they don't apply to be inc. in CA....
bull
MACD getting ready to crossover...the last time it crossed over under 0 like this was on 1/2/14 @ around 11 cents....and we all know what happened after that...
bull
Do you see them growing anything yet..they said the first part was going to be the container park...I don't think they need an agriculture anything to grow containers...
bull
They are incorporated in Nevada
They are not incorporated in California...so they would not be listed on the sight you and your alias keep listing here....
this sight is for businesses incorporated in California..they are not going to be listed on it...http://kepler.sos.ca.gov/
cut the crap
bull
https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=EsbjiFttxOUl45QvJt71vQ%253d%253d&nt7=0
I guess we have our answer....you are not a man of your word...
Did you or did you not just post this....
"I'll make you a deal. You post an active business license from Extreme Biodiesel and I will leave the board for good. "
I found one...I posted one...so do what you said you would and leave the board for good....
or is your word not worth the crap you post
bull
https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=EsbjiFttxOUl45QvJt71vQ%253d%253d&nt7=0
bye bye
bull
Extreme Green Technologies, Inc. dba Extreme Biodiesel (EGT)
you do know what a dba is don't you...
cut the crap
bull
they bought EXTREME GREEN TECHNOLOGIES INC. .....and they don't use that name.....that name does not exist anymore
cut the crap
bull
This two-arm study will see Nuvilex's treatment going head to head with Celgene's treatment of Abraxane plus gemcitabine.
I'm sure Austrianova has not stopped working on Cell_in_a_Box all this time...I guess we will have to wait until the trial to find out if there are new changes...
but you are right about everything...
bull
Phase 2b is being done for comparison to the new gold standard set by Celgene back in the fall when they got approval for Abraxane as a first-line treatment in combo with gemcitabine.....
the other Phase I/II trials were only compared to gemcitabine...
bull
OTC Journal Newsletter May 1, 2014
Nuvilex (NVLX): Proving My Theory Today
The last edition I published on Nuvilex (NVLX) back on April 19th suggested we had finally arrived at a point where news on positive fundamental developments would be the driver of price movement in shares of NVLX.
As all long term investors in this name understand, the key to more upside in the stock centers around moving their technology towards FDA and International approvals, which they are now doing rapidly.
Of late, the company has engaged Transitional Drug Development, headed by world renowned cancer specialist Daniel Von Hoff to prepare for clinical trials. NVLX has engaged ViruSure of Vienna, Austria to develop and maintain their working cell banks.
NVLX has also retained Clinical Network Services as a Contract Research Organization to manage planned clinical trials in Australia, New Zealand, and the United Kingdom.
The company has also raised $4 million on very favorable terms in the last 6 months, and been pledged another $27 million.
Throughout the entire process, the company has come under fire by detractors that consistently have now been proven wrong.
As the company puts all the pieces in place to start the clinical trial process, the character of the way this stock trades has changed.
Now, I believe the stock will be primarily news driven, with market conditions in the background having an influence as well, rather than being driven by traders who are only concerned with price movement.
Today was a good case in point. NVLX was up nicely - about 10% today, on the news another world renowned Oncologist will play a major role in the pending Late Phase Clinical Trials.
According to today's news, Professor Matthias Lohr of the famed Karolin-ska Institute in Stockholm, Sweden, will be playing a major role Nuvilex's planned Phase 2B trial in Australia. Dr. Lohr was a member of the team the did the first clinical studies at Germany's Rostock Hospital on 14 late stage Pancreatic cancer patients.
I believe we may have arrived at a point where NVLX will trade more on fundamental progress, and less on whether or not the stock is going up or down.
And, I suspect we will see a lot more fundamental progress.
There is going to be a whole word of Doctors working on different uses for Cell_in_a_Box....
Pancreatic Cancer Research Team (PCRT) are enthusiastic to begin clinical trials with this approach....meaning different Doctors with different diseases....all at the same time....while we do our Phase 2b.....
bull
that is because they have their name registered in Nevada...
give it up.....cut the crap
bull
Safety and proof of principle have already been demonstrated in the phase I/II clinical trial....2b is specifically because of Celgene's approval...to go head to head....then we take the gold standard...
and the 2b Trial is cheaper to run...so Nuvilex would save a ton of money if they get Accelerated Approval after 2b....
bull
they posted it to show that Austrianova already received Orphan Drug Designation before so there is no reason they won't get it for the Phase 2b Trial...
bull
Cell_in_a_Box / NovaCaps granted Orphan Drug designation before...
Austrianova received Orphan Drug designation for NovaCaps from the European Medicines Agency (EMEA) in July 2003....
it's a gimme this time..
bull
this refutes septmike ....and you... since you are one in the same...
you are missing the point as usual...
but to simplify it for you....they forfeited the name...you know gave it up themselves when they acquired Extreme Green Technologies....
so cut the crap....
bull
Company Applies for Updated Symbol Reflecting New Corporate Identity
Extreme Biodiesel Files Request for Symbol Change with FINRA
April 29, 2013 09:30 AM Eastern Daylight Time
CORONA, Calif.--(BUSINESS WIRE)--Extreme Biodiesel (Pink Sheets: BRKM) is pleased to announce that the Company has successfully filed the documents with the Financial Industry Regulatory Authority ("FINRA") to officially recognize the recently completed name change from BookMerge Technologies to Extreme Biodiesel, and request a new trading symbol. Management will notify shareholders when the request has been approved and the new symbol takes effect.
“We appreciate the loyal support of our shareholders as we continue to grow and evolve. It is anticipated that this year will bring many results from the momentum we have built in the process”
Extreme Green Technologies, Inc. was acquired by BookMerge Technologies in 2010, and has since become the sole focus of the Company. Extreme Green Technologies, Inc. was developed in 2003 with the express purpose of producing, distributing, and creating awareness of user-friendly alternative energy products and sources of power. By entering into the quickly expanding biofuels industry, the Company's primary focus is to produce a user-ready, high quality alternative fuel that is priced competitively with petro-diesel. Because there is an impending need to stop global warming and reduce humankind's carbon footprint, Extreme Green Technologies continuously strives to seek out new technologies and produce feasible eco-friendly fuels in order to make a positive impact on both the environment and our domestic economy.
The Company has recently engaged in negotiations with a couple of existing clients; reputable revenue generating companies in the biofuels industry, in an effort to expand its business model and enhance revenues. Extreme Biodiesel seeks to be an emerging West Coast industry leader through the Company’s aggressive acquisition and growth strategy.
“We appreciate the loyal support of our shareholders as we continue to grow and evolve. It is anticipated that this year will bring many results from the momentum we have built in the process,” stated Joe Spadafore, President and Chief Executive Officer of Extreme Biodiesel.
About Extreme Biodiesel: Extreme Biodiesel is a Company dedicated to the production of ecologically friendly biodiesel energy products. The Company's state-of-the-art solutions are designed to provide a realistic means for dramatically reducing the United States' dependence on foreign oil. Extreme Biodiesel entered the industry in 2003 with the creation of biodiesel processors designed chiefly for individual end-users. Extreme Biodiesel is further expanding its scope by increasing biodiesel production and also creating a Co-Op for both individual members and fleet accounts throughout Southern California.
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
cut the crap...
bull
COCP was a private company...hence the lack of anything...give it a chance...it just went public...
bull
from the annual report tomorrow we should be able to see what is left to do to ready for phase 2b...maybe even an update on Dr. Von Hoff....
bull
Annual Report...comes out tomorrow on 4/30...should get some insight to where we are on trials..
bull
I liked him also...he responded to my emails in a timely manner...the thing now is that Nuvilex is outgrowing him...they need a strong high profile results driven IR/PR firm like this....that will bring in bigger investors..in my opinion this move could not have come at a more timely manner with us going into 2b trials...they will be so beneficial to the company....did you look on their website...
bull
Nuvilex has a new IR/PR company
CorProminence Management Is Comprised Of Senior Market And Practice Leaders With Over 70 Years Of Collective Expertise In Their Respective Specialties. It Is This Synergy Which Enables Corprominence To Bring Our Unique And Highly Effective Results To Bear For Clients Within Such A Wide Array Of Industries And Sectors.
http://www.corprominence.com/
HIGH VISIBILITY - HIGH PERFORMANCE
INTEGRATED INVESTOR & PUBLIC RELATIONS
CORVIDEO™ enhances your online message and facilitates engagement with investors through personal video interviews with key members of the management team.
The IR-NEWSROOMS channel provides an investor destination to deliver your latest news and media updates.
check it out
bull
Yes you are reading it wrong....
I have read about cytochrome P450....and they are essential for the metabolism of a lot of medications....six of them metabolize 90 percent of drugs...
I still don't get your point...so I think I will just leave it up to the accomplished team of doctors who have been put together to finish what was started with Cell_in_a_Box and Bac_in_a_Box...
I have a strong feeling they know a lot more than you and I and everyone on here....
bull
You do understand what Cell_in_a_Box is don't you...
Use of encapsulated cells for cancer cell therapy from genetically modified cells over-expressing a chemo-activating enzyme to allow lower doses of chemotherapy to be used more efficaciously without the usual debilitating side effects.
It is used for inoperable pancreatic cancer...these are people who have been given a death sentence....nothing more can be done for them....it has been proved to extend the length of time they stay alive and the quality of life during that time....we are talking maybe a yr or 2....so talking about any future side effects seem to be fruitless...
and if after it is approved other pharmas are able to use it to prolong life and give better quality of life in their fight to cure different cancers than that will be great...
Nuvilex does not produce any drugs...it is a tool to deliver..
bull
What I see here is no one wants to sell their shares of Nuvilex...I don't see any dumping going on...I see accumulation of a great little bio stock that won't be little for long....
bull
this little bio is just getting started...and they are moving fast lately to get all the ducks in a row...I think from now on the news is going to move the stock...it just has to gain some stability for the investors to get in...but all the news that we will read now will be important steps to the initiation of phase 2b.....the last several pr's have been important ...
and when you hear enrollment of patients....you will feel good you have your core position down here in these ridiculously low prices...
what small bio going into the final stages of getting something like Cell_in_a_Box approved can you find at this pps...NONE
bull
Let's just lay this to rest about dilution since every company issues shares including Nuvilex....and we can get back to the business of talking about all the important steps that Nuvilex is making to bring phase 2b trials to fruition....
bull
Nuvilex is part owner of Austrianova because they were going to buy the whole company....until they realized they didn't need to do that...they bought Bio Blue Bird AG (BBB) the part that held the licenses to the Cell_in_the_Box technology which they wanted....and in turn returned millions of shares of stock back to the treasury for the stockholders...they were looking out for us....
so my question to you would be ...what is the problem with that?
for your other comment...there are side effects to chemo...whatever kind of chemo and whatever kind of cancer....
Cell_in_the_Box is not a cure to cancer...it is a start to a cure in cancer...1/3 the chemo is used with better results and less side effects than the only 2 standards out there...there was only one standard until last fall with Celgene's approval...and Nuvilex's technology has already shown to be better than both of them in their Phase I/II trials....
so I don't understand your 2 comments at all ....
bull
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
we are moving rapidly toward 2b trial.....
and this should put to rest any concerns about the patents....
While there are currently long-term patents on Nuvilex's pancreatic cancer treatment, receiving Orphan Drug status will allow the Maryland biotech firm to exclusively market the Cell-in-a-Box® technology combined with ifosfamide long after those patents expire.
bull
We know they will get Orphan Drug Status because Austrianova already received it once before.....
EMEA previously granted Orphan Drug Status for this product which gave:
Free Protocol Advice
“fast track” thro‘ further clinical trial design together with EMEA
Up to ten years market exclusivity
Successful clinical trials using the Cell-in-a-Box® principal:
Use of encapsulated cells for cancer cell therapy from genetically modified cells over-expressing a chemo-activating enzyme to allow lower doses of chemotherapy to be used more efficaciously without the usual debilitating side effects. Shown to be safe and efficacious in early phase clinical trials
Product:
A cell based therapeutic consisting of cells genetically modified to over-express cytochrome P450 encapsulated in biologically inert cellulose sulphate polymers
– one “off the shelf “ product for all patients
Mechanism of Action:
The encapsulated cells are placed, using supraselective catheterisation, into blood vessels leading to the tumor where they locally convert a chemotherapeutic prodrug to its tumor toxic product
Proven Safety in the clinic:
Phase l/II Trial design
Advanced non-resectable pancreatic cancer
14 patients treated
One dose of 300 microcapsules
Delivered by catheter into tumor artery
1/3 dose chemotherapy
Therapeutic Effect shown through Tumor Reductions:
A second, confirmatory trial involving more clinical centers was undertaken. The overall Results of Clinical Trial:
Safety
Proven safety record in all 27 patients
No obvious immune or inflammatory response to cells or capsule material
Efficacy
Double survival rate over gold standard
Tumor shrinkage
Improvement in Quality of Life
Lower dose ifosfamide gives a similar survival benefit but fewer side effects
In addition
the treatment strategy and technology recognized by regulatory authorities EMEA, TGA, FDA, HSA
EMEA previously granted Orphan Drug Status for this product which gave:
Free Protocol Advice
“fast track” thro‘ further clinical trial design together with EMEA
Up to ten years market exclusivity
Results published in peer-reviewed journals such as Lancet, Cancer Therapy, Gastroenterology
bull
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition
NEW YORK, NY--(Marketwired - Apr 22, 2014) - When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for "Orphan Drug" status. This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide. Treatments for pancreatic cancer engender an Orphan Drug designation in most countries and that alone enables companies receiving the status to sell their approved treatment without competition for an additional 7 years in the US and 10 years in Europe.
While there are currently long-term patents on Nuvilex's pancreatic cancer treatment, receiving Orphan Drug status will allow the Maryland biotech firm to exclusively market the Cell-in-a-Box® technology combined with ifosfamide long after those patents expire.
Nuvilex announced that CNS will immediately provide consulting and management services as part of implementing the company's global regulatory strategy, including applying for the Orphan Drug designation from the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA).
The Orphan Drug designation is given to treatments for "rare" diseases, and the FDA can award the status long before a treatment is approved for use. In the US, diseases like pancreatic cancer that are diagnosed in less than 200,000 people annually, are eligible for this designation, meanwhile, in Europe, the designation is reserved for diseases occurring in less than 5 out of every 10,000 people, so Nuvilex's treatment should easily qualify.
In 2007, both the FDA and EMA moved to reduce the burden on those applying for Orphan Drug status by agreeing to use a common application process for both agencies.
Getting Accelerated Approval
It's a game plan that could include obtaining accelerated FDA approval of its pancreatic cancer treatment if it can produce the same strong results in an announced Phase 2b clinical trial that were produced in two separate Phase 1/2 trials using the combination of the Cell-in-a-Box® technology with the anticancer drug ifosfamide.
oh yeah WE ALREADY DID THAT...beat out the other 2 standards...
The market may want to start connecting the dots with this international biotech because as Nuvilex releases each piece of its story, the path is leading to more and more impressive hands guiding Cell-in-a-Box® and Nuvilex right to the FDA's door.
oh yeah WE HAVE THE DR. WHO CAN TAKE US THERE....
Dr. Von Hoff is the World's Leading Authority on Pancreatic Cancer & Now He will Lead Nuvilex's Clinical Trials
Dr. Von Hoff Developed Eli Lilly's Gemzar®
Dr. Von Hoff Developed Celgene's Abraxane®
The same developer who has turned into an FDA Approval Machine. As the World's Leading Expert on Pancreatic Cancer, the FDA seems to approve everything Dr. Von Hoff touches related to the disease!!
What investors may not realize is that through the FDA's Accelerated Approval Program, Nuvilex could receive FDA approval of its pancreatic cancer treatment using Phase 2b data. If CNS can once again lead the combination of Cell-in-a-Box® with ifosfamide to the same powerful results it generated in prior trials that still today outperform Eli Lilly's Gemzar® and Celgene's treatment, the FDA could grant accelerated approval for the treatment. This program is one of several tools used by the FDA to expedite the approval of medicines intended to treat serious or unmet needs.
oh yeah...THE KEY WORDS ARE ONCE AGAIN....just like last trials...
The FDA's Accelerated Approval Program allows for the approval of an investigational drug or treatment based on a surrogate endpoint (a measurement that can "stand in" for an accepted measurement of disease progression) in early-phase studies if the condition is serious or life-threatening, and Nuvilex should have an excellent case for just such an approval.
If that were to happen, the company may or may not be required to conduct a Phase 3 trial while its treatment is being used by patients with advanced, inoperable pancreatic cancer. It would, however, undergo a Phase 4 or "confirmatory study" to further evaluate and confirm the efficacy and safety of the treatment, but it would do so with Cell-in-a-Box® combined with ifosfamide on the market.
oh yeah....PANCREATIC CANCER IS A DEATH SENTENCE....
that about covers it...
bull
XTRM is just getting started...it is going to take time....with the new lease at 28030 Hwy 74, Lake Elsinore, CA 92570.
It houses an office, a working garage, along with the additional space needed for storage of biodiesel equipment...and the land...they are setting up for the future...
bull
Nuvilex rides the waves like the other bio's.....so don't be so sure about that...Biotech starts reporting next week....along with big tech companies...S&P 500...63% of co.'s reported have beaten estimates so far....and England does not seem to have a problem with Gilead's Sovaldi treatment price...they just bought $31M worth from them....
bull